Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM4 | O15151 | 3/20 | 0.61 |
| ▸ | TP53 | P04637 | 3/20 | 0.61 |
| ▸ | CASP3 | P42574 | 3/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | MDM2 | Q00987 | 5/20 | 0.52 |
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL118370 | 1.00 | MDM4 (0.61) | MDM4TP53CASP3KMT2AMDM2 | |
| SCHEMBL30977677 | 1.00 | MDM4 (0.61) | MDM4TP53CASP3KMT2AMDM2 | |
| SCHEMBL29366757 | 1.00 | MDM4 (0.61) | MDM4TP53CASP3KMT2AMDM2 | |
| SCHEMBL29613402 | 1.00 | MDM4 (0.61) | MDM4TP53CASP3KMT2AMDM2 | |
| SCHEMBL12537019 | 1.00 | MDM4 (0.61) | MDM4TP53CASP3KMT2AMDM2 | |
| SCHEMBL1486216 | 1.00 | MDM4 (0.61) | MDM4TP53CASP3KMT2AMDM2 | |
| SCHEMBL29907974 | 1.00 | MDM4 (0.61) | MDM4TP53CASP3KMT2AMDM2 | |
| SCHEMBL29519824 | 0.95 | MDM4 (0.57) | MDM4TP53CASP3KMT2AMDM2 | |
| SCHEMBL6742006 | 0.92 | MDM4 (0.55) | MDM4TP53CASP3KMT2AMDM2 | |
| SCHEMBL29451083 | 0.91 | CASP3 (0.59) | MDM4TP53CASP3KMT2AMDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 634 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122036916-A | Ruitalu Process for producing peptide | 哈尔滨吉象隆生物技术有限公司 | 2026-05-15 | — | — | CN | claimed |
| US-20260116848-A1 | Synthesis of an Intermediate and Its Use for the Preparation of GLP-1R/GIPR Agonists | CARMOT THERAPEUTICS INC. (US) | 2026-04-30 | — | — | US | claimed |
| CN-119350469-B | Method for synthesizing CAGRILINTIDE by large fragment SPPS-LPPS mixing method | 杭州诺澳生物医药科技有限公司 | 2025-05-23 | — | — | CN | claimed |
| CN-119818387-A | Application and synthesis method of cyclic peptide | 上海中翊日化有限公司 | 2025-04-15 | — | — | CN | claimed |
| CN-119529056-A | Solid phase preparation method of telipopeptide | 福建基诺厚普生物科技有限公司 | 2025-02-28 | — | — | CN | claimed |
| CN-119371515-A | Synthesis method of salmon calcitonin acetylation impurity | 翰宇药业（武汉）有限公司 | 2025-01-28 | — | — | CN | claimed |
| CN-119350469-A | Method for synthesizing CAGRILINTIDE by large fragment SPPS-LPPS mixing method | 杭州诺澳生物医药科技有限公司 | 2025-01-24 | — | — | CN | claimed |
| CN-117986349-B | Semex lattice preparation method of lupeptide | 福建基诺厚普生物科技有限公司 | 2024-10-01 | — | — | CN | claimed |
| CN-118221762-A | Preparation method of antibacterial polypeptide derivative | 沈旭 | 2024-06-21 | — | — | CN | claimed |
| CN-114806589-B | Living algae composition and preparation method and application thereof | 仲恺农业工程学院 | 2024-05-24 | — | — | CN | claimed |
| CN-111944016-B | Preparation method of icatibant acetate | 台州吉诺生物科技有限公司 | 2022-04-29 | — | — | CN | claimed |
| CN-111318187-B | Chiral separation membrane based on covalent organic framework material, preparation and application thereof | 南开大学 | 2022-04-12 | — | — | CN | claimed |
| CN-113135988-B | Preparation method of thymosin beta 4 | 润辉生物技术（威海）有限公司 | 2022-04-01 | — | — | CN | claimed |
| CN-113121673-B | Method for preparing elcatonin by solid-liquid combination method | 润辉生物技术（威海）有限公司 | 2022-03-29 | — | — | CN | claimed |
| CN-114249808-A | Synthesis method of Cagrilintide | 杭州诺泰澳赛诺医药技术开发有限公司 | 2022-03-29 | — | — | CN | claimed |
| CN-114230633-A | Polypeptide with oxidative stress damage repairing function and preparation method and application thereof | 浙江湃肽生物有限公司深圳分公司 | 2022-03-25 | — | — | CN | claimed |
| CN-114057862-A | Synthetic method of GLP-1(1-37) polypeptide | 安徽省国平药业有限公司 | 2022-02-18 | — | — | CN | claimed |
| CN-109180803-B | Somatostatin and preparation method and pharmaceutical composition thereof | 成都天台山制药有限公司 | 2022-02-08 | — | — | CN | claimed |
| CN-113999289-A | Preparation method of goserelin | 杭州信海医药科技有限公司 | 2022-02-01 | — | — | CN | claimed |
| CN-113956332-A | Near-infrared probe with high affinity for early gastric cancer and preparation method thereof | 中国人民解放军空军军医大学 | 2022-01-21 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260116848-A1 | Synthesis of an Intermediate and Its Use for the Preparation of GLP-1R/GIPR Agonists | GLP1R, GIPR, CCKBR | MDM4 4227/4885TP53 4727/4885CASP3 3659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.